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Abstract
Low-density lipoproteins (LDLs) are a naturally occur-
ring endogenous nanoplatform in mammalian systems.
These nanoparticles (22 nm) specifically transport
cholesterol to cells expressing the LDL receptor (LDLR).
Several tumors overexpress LDLRs presumably to pro-
vide cholesterol to sustain a high rate of membrane
synthesis. Amphiphilic gadolinium (Gd)-diethylenetria-
minepentaacetic acid chelates have been incorporated
into the LDL to produce a novel LDLR-targetedmagnetic
resonance imaging (MRI) contrast agent. The number
of Gd chelates per LDL particle ranged between 150 and
496 Gd(III). In vitro studies demonstrated that Gd-
labeled LDL retained a similar diameter and surface
charge as the native LDLparticle. In addition, Gd-labeled
LDL retained selective cellular binding and uptake
through LDLR-mediated endocytosis. Finally, Gd-
labeled LDLs exhibited significant contrast enhance-
ment 24 hours after administration in nude mice with
humanhepatoblastomaG2 xenografts. Thus,Gd-labeled
LDL demonstrates potential use as a targeted MRI con-
trast agent for in vivo tumor detection.
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Introduction
Nonspecific paramagnetic contrast agents, such as gadolin-
ium-diethylenetriaminepentaacetic acid (Gd-DTPA) and
other Gd chelates, have greatly improved the diagnostic ca-
pabilities of magnetic resonance imaging (MRI) [1–4]. These
agents augment intrinsic tissue contrast, thereby enhancing
soft tissue discrimination as well as providing important
physiological information about perfusion, vascular perme-
ability, and extracellular volume [5,6]. The recent develop-
ment of targeted paramagnetic contrast agents promises
to greatly expand the diagnostic specificity of these agents
[7–9]. By targeting specific cell surface epitopes, these
agents will enable imaging of specific cell populations in vivo.
Although MRI provides high spatial resolution, it suffers
from low inherent sensitivity [10]. In addition, the limited
number of cell surface epitopes suitable for targeting im-
pedes their detection by targeted MRI contrast agents. The
use of nanoplatforms (nanoscale structures typically smaller
than 100 nm) to simultaneously deliver multiple Gd chelates
may overcome this limitation. Most of the existing nanoplat-
forms consist of synthetic nanostructures, such as dendrimers
[11], silica-coated micelles [12], polymeric and ceramic nano-
particles [13,14], perfluorocarbon emulsions [15], and cross-
linked liposomes [16]. In addition to attaching diagnostic agents,
specific moieties, typically small peptides, peptidometics, or
antibodies, have been conjugated to the platform to impart tar-
geting capabilities [17–20]. Although many of these particles
have shown good targeting with high payloads of Gd(III), their
large size confined them to the vascular compartment [18,21].
The utility of these synthetic nanoparticles is often limited by
biocompatibility, biodegradability, and toxicity problems.
Low-density lipoproteins (LDLs) are naturally occurring nano-
structures that serve as the main transport vehicles for choles-
terol in mammalian systems [22]. LDL particles contain a
phospholipid monolayer encapsulating a hydrophobic core.
Spanning the phospholipid monolayer is the apolipoprotein
B-100 (ApoB-100), a very large amphipathic protein containing
one or more clusters of cationic amino acids that target LDL
receptors (LDLRs) on cells. After binding to the LDLR, LDL is
internalized by endocytosis. Within lysosomes, LDL particles are
degraded into amino acids, fatty acids, and free choles-
terol, whereas the receptor is recycled to the cell surface.
Given LDLR recycle time is only 10 minutes and its lifetime is
24 hours, this receptor pathway efficiently transports many LDL
particles to LDLR-expressing cells. In addition to a number of
normal tissues such as the liver, adrenal glands, and ovaries,
which use the LDLR system, several tumors overexpress the
LDLR [23–30]. Several investigators have used LDLs to selec-
tively deliver diagnostic and/or therapeutic agents to LDLR-
overexpressing tumors [31]. For diagnostic purposes most
of these efforts have focused on attaching radionuclides to
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ApoB-100 [32,33] or intercalating radiolabeled amphiphilic
conjugates into the LDL phospholipid monolayer [34,35].
Alternatively, near-infrared fluorescent probes have been
attached to LDLs for tumor detection [36,37]. Although all of
these studies were performed ex vivo or in cell culture, they
have generated promising results that have shown selective
uptake of labeled LDL by cells/tissues expressing LDLR. To
date, few studies have gone on to assess the utility of these
probes for in vivo tumor detection. Ponty et al. [38] used
99mTc-LDL to visualize B16-melanoma xenographs in mice.
Scintigraphic images demonstrated accumulation of the la-
beled probe in the upper abdomen and in the region of the
tumor xenograft; however, the poor spatial resolution of
these images impaired anatomical demarcation of organ or
tumor boundaries. To overcome these problems, members
of our group have attempted to use paramagnetic labeled
LDL for tumor detection with MRI [39]. This prototype con-
trast agent (PTIR267) contained both a fluorophore and a
Gd(III) moiety along with two palmitate hydrocarbon chains,
which facilitated intercalation into the LDL phospholipid mono-
layer. Fifty molecules of PTIR267 were attached to each
LDL, and subsequent IV administration of this agent into a
B16 tumor–bearing mouse demonstrated accumulation of
labeled LDL within the liver and tumor. Although this initial
finding clearly demonstrated the feasibility and potential of
the LDL platform, a number of problems limit its utility. The
current formulation of PTIR267 (fluorophore, Gd-DTPA moi-
ety, and bis-palmitate chains) produces a bulky and sterically
hindered molecule; hence, only a limited number (upper limit
of 50) of this contrast agent can be intercalated into the LDL
phospholipid monolayer. This becomes a critical issue for MR
molecular imaging as high paramagnetic payloads are re-
quired to overcome the low inherent sensitivity of MRI. One
method of delivering more Gd(III) to the target site would be
to simply increase the amount of administered PTIR267; this
approach, however, could elicit anaphylactic reactions and
toxicity due to the high concentrations of protein and fluores-
cent dye. Clearly, alternate approaches are necessary to
further optimize the diagnostic utility of paramagnetically
labeled LDL. In the present study, a more versatile and less
bulky amphiphilic Gd chelate was synthesized. Due to the
simple structure of this agent, it was possible to incorporate
much higher payloads (150–500) of the probe into LDL.
Preparation of paramagnetic labeled LDL was performed in
two steps: first the amphiphilic chelate was incorporated into
LDL, and second chelation with Gd(III) was performed to
produce the novel LDLR-targeted MRI contrast agent. Here
we evaluate the characteristics and binding properties of this
Gd(III)-labeled LDL and assess the diagnostic utility of this
agent for detecting tumors overexpressing LDLR in vivo.
Materials and Methods
Preparation and Characterization of Gd-Labeled LDL
Nanoparticle Preparation of DTPA-bis(stearylamide)
DTPA-bis(stearylamide) (DTPA-SA) was prepared by the
method of Jasanada et al. [34]. Briefly, stearylamine (0.54 g;
2 mmol) in chloroform (40 ml) was slowly added to the bis-
anhydride of DTPA (0.40g; 1.1 mmol) in DMF (50 ml). After
2 hours of stirring at 40jC, the solution was cooled at 4jC
for 2 hours. The white precipitate was filtered, washed with
acetone, and dried overnight at 80jC. The precipitate was
then crystallized in boiling ethanol (800 ml). After 24 hours at
room temperature, the small crystals were collected by fil-
tration and washed with water (800 ml, 80jC for 3 hours) and
chloroform (800 ml, reflux for 3 hours) to eliminate unreacted
DTPA and SA.
Low-Density Lipoprotein
LDL was isolated from fresh plasma of healthy donors by
sequential ultracentrifugation as described previously by
Lund-Katz et al. [40].
Incorporation of DTPA-SA into LDL
A 3.0 mM solution of DTPA-SA was prepared by dissolv-
ing the crystals in aqueous ammonia solution (NH4OH/
NH4Cl, pH 9, 0.15 M) with vigorous stirring and gradual heat-
ing to approximately 40jC. Once the crystals had dissolved,
the clear solution was diluted to a concentration of 1.5 mM
with Tris-buffered saline. The DTPA-SA and LDL were mixed
at a molar ratio of 200:1. First, an aliquot of the DTPA-SA
solution was diluted with Tris-buffered saline (to 0.35mg/ml)
and adjusted to pH value 8.0 with HCl (1 M). The DTPA-SA
solution was added dropwise to the LDL solution. The final
concentration of LDL was 0.4 mg/ml. After stirring under N2
for 1 hour at room temperature, the sample was filtered
through a 0.22-mm membrane filter and dialyzed against
Tris-buffered saline overnight (16 hours) at 4jC. Any
DTPA-SA that precipitated during dialysis was removed
by membrane filtration (0.22 mm). The amount of DTPA-SA
incorporation into LDL was determined by UV spectrometry
using the zinc dithizone assay [34]. LDL particles labeled
with higher payloads of DTPA-SA (up to molar ratio of 500:1)
were also performed by the methods described above.
LDL Determination
The molar concentration of LDL was determined by total
protein analysis using a commercial Lowry protein assay
kit (Sigma-Aldrich, St. Louis, MO) on the assumption that
ApoB-100 (550 kDa) was the only protein present with one
protein per LDL particle.
Gadolinium Labeling
Gd citrate solution was prepared by adding GdCl3
(17.5 mmol) in HCl to a solution of sodium citrate (87.5 mmol).
Excess citrate was used to avoid formation of insoluble
hydroxides. The pH of the Gd citrate solution was adjusted
to 7.4 with HCl/NaOH. Gd(III) labeling of DTPA-SA-LDL was
performed by slowly adding Gd citrate to a solution of DTPA-
SA-LDL at a metal/chelator ratio of 1:1. After incubation for
1 hour at room temperature under N2 with gentle stirring, the
product was filtered, and a dilute solution of tropolone
(10 mmol/L) was added in excess (15) to eliminate any
nonspecific binding of Gd(III) to LDL. The solution was gently
stirred for 1 hour at 4jC and the final product was filtered.
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The solution was concentrated down to a volume of 500 ml
with a 15-ml Centricon centrifugal filter unit (Millipore, Bil-
lerica, MA).
Light Scattering
The particle size distributions of native and modified LDL
were measured by light-scattering photon correlation spec-
troscopy (Zetasizer 3000HS, Malvern Instruments, Malvern,
UK) utilizing a 10-mWHe-Ne laser operating at 633 nm and a
detector angle of 90j. The data were modeled assuming
spherical particles undergoing Brownian motion.
Electron Microscopy Studies
Transmission electron microscopy with a JEOL JEM 1010
electron microscope equipped with a charge-coupled device
camera (Hamamatsu, Middlesex, NJ) operating at 80 kV
using AMT 12-HR software (Advanced Microscopy Tech-
nique, Danvers, MA) was used to determine the morphology
and the size of the aqueous dispersion of nanoparticles. Five
microliters of lipoprotein nanoparticle suspension was placed
on carbon-coated 200-mesh copper grids and allowed to
stand for 5 minutes. Excess sample was removed with lens
paper, and 2% saturated aqueous uranyl acetate was ap-
plied to the grid in five consecutive drops within 20 seconds.
The stain was then drained off with filter paper, and the grid
was air dried before digital images were taken. All electron
microscopy supplies were purchased from Electron Micros-
copy Sciences (Fort Washington, PA).
Agarose Electrophoresis
The electrophoretic properties of LDL particles were ex-
amined by 0.5% argarose gel electrophoresis. Samples in
Tris-saline buffer (6 mg protein in 4 ml) were applied to gel
wells and allowed to penetrate into gel for 5 minutes before
the electric field was applied. A Bio-Rad model 702 power
supply was used to apply a voltage of 100 ± 2 V across a
gel distance of 5.5 cm. Electrophoresis was continued for
30 minutes at 25 ± 2jC in barbital buffer (pH 8.6, 0.05 ionic
strength). After electrophoresis, the gels were fixed in a
solution of ethanol/acetic acid/water 60:10:30 (vol/vol/vol),
oven-dried (80jC for 1 hour), and then stained (5 minutes)
with a 0.15% Coomassie Blue R250 solution. Gels were de-
stained in a solution of methanol/acetic acid/water 35:25:
40 (vol/vol/vol) for about 10 minutes or until the background
adjacent to the LDL bands was clear and the stain intensity
of the bands was uniform.
Determination of Longitudinal Relaxivities
The proton longitudinal relaxation rates (1/T1) of gado-
diamide and Gd-labeled LDL (Gd-DTPA-SA-LDL) were mea-
sured at 21 and 40jC on an mq60 Minispec NMR Analyzer
(Bruker, Inc., The Woodlands, TX) at a field strength of
60 MHz. The contrast agents were prepared in saline, and
T1 was measured with an inversion recovery pulse sequence
using 10 to 20 inversion delay values. The T1 relaxivities
were calculated from the slope of a plot of the longitudinal
relaxation rates versus Gd3+ concentrations (millimolar).
Assessment of LDLR-Mediated Uptake
of Gd-DTPA-SA-LDL
To determine the specificity of Gd-DTPA-SA-LDL uptake
by LDLR, cell culture experiments were performed with MRI
and optical imaging techniques.
Cell culture
Human hepatoblastoma cancer cell line (HepG2) (over-
express LDLR) and ldlA7 [LDLR-negative Chinese hamster
ovary (CHO) cells] [41] were obtained from Drs. Theo van
Berkel (University of Leiden, Netherlands) andMonty Krieger
(Massachusetts Institute of Technology, Cambridge, MA), re-
spectively. HepG2 cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal bo-
vine serum (FBS) and 100 U/ml penicillin-streptomycin.
ldlA7 were cultured in DMEM/F-12 medium (Ham’s
nutrient mixture) supplemented with 100 U/ml penicillin-
streptomycin, 2 mM L-glutamine and 5% fetal bovine serum
(FBS). Cells were grown at 37jC in an atmosphere of 5%
CO2 in a humidified incubator.
Magnetic Resonance Imaging
Three and a half million cells each of HepG2 and ldlA7
grown in T25 Corning flasks (Sigma-Aldrich) were incubated
with 0.44 mM Gd-DTPA-SA-LDL for 5 hours at 37jC. An
additional flask of HepG2 was incubated in the presence
of Gd-DTPA-SA-LDL and a six-fold concentration of native
LDL. After this incubation period the cells were washed
three times with PBS, trypsinized, and centrifuged (1000 rpm
for 5minutes) to pellet the cells. The total volume of the sample
(pellet and fresh PBS) was approximately 150 ml. Cells not
exposed to the contrast agent served as untreated controls.
MRI evaluations were performed on the cell samples using
the 4.7-T Varian magnet (Palo Alto, CA). Sagittal T1-weighted
MR images were acquired with a spin-echo sequence (TR/
TE=500/15 ms, matrix = 256 128 and FOV = 6 3 cm, slice
thickness = 1 mm, signal average =4).
Preparation of Gd-DTPA-SA tetra-t-Butyl Silica
Phthalocyanine Bisoleate–Reconstituted LDL
The near-infrared dye tetra-t-butyl silica phthalocyanine
bisoleate (SiPc-BOA) was reconstituted into the core of
LDL by a minor modification of the method of Krieger et al.
[42]. Briefly, 1.9 mg of dialyzed LDL was lyophilized with
25 mg starch in Siliclad-treated glass tubes. Then the LDL
was extracted three times with 5 ml of heptane at 10jC.
After aspiration of the last heptane extract, 6 mg of SiPc-
BOA was added in 200 ml of benzene. After 90 minutes at
4jC, benzene and any residual heptane were removed
under a stream of N2 in an ice-salt bath. After about 45 to
60 minutes, completely dried reconstituted LDL was solu-
bilized in 10 mM Tricine (pH 8.2) at 4jC for 24 hours. Starch
was removed from the solution by low-speed centrifuga-
tion, and the specimen was further clarified by at least one
or two additional centrifugations. SiPc-BOA–reconstituted
LDL (abbreviated as r-SiPc-BOA-LDL) was stored under
N2 at 4jC. The Gd-DTPA-SA was then intercalated into
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the phospholipid monolayer of r-SiPc-BOA-LDL (as de-
scribed above).
Confocal Microscopy
Laser scanning confocal microscopy studies were per-
formed on HepG2 cells to determine whether Gd-DTPA-
SA(r-SiPc-BOA)-LDL was internalized through LDLRs. In
brief, HepG2 cells grown on four-well Lab-Tek chamber slides
(Naperville, IL) were washed with preincubation medium con-
taining the indicated amounts of Gd-DTPA-SA(r-SiPc-BOA)-
LDL/r-SiPc-BOA-LDL and/or unlabeled LDL. After 4 hours’
incubation at 37jC, the cells were washed with ice-cold PBS,
fixed with 3% formaldehyde in PBS, and mounted and sealed
for confocal microscopic analysis. Confocal microscopy was
performed with a Leica TCS SPII laser scanning confocal
microscope (Heidelberg, Germany). The filter settings were
633 nm for excitation and 638 to 800 nm for emission.
Experimental Animals and Induction of Ectopic Tumors
The following protocol was approved by the University of
Pennsylvania Animal Ethics Committee. Adult female nude
mice (26–29 g) were allowed free access to food and water
throughout the study. HepG2 cells (10  106; overexpress
LDLR) were inoculated subcutaneously into the left flanks of
nude mice. Six weeks after tumor inoculation, mice were
designated as either control or treated animals.
In Vivo MRI Imaging
Contrast agents Gd-DTPA-SA-LDL (170:1) or gadodi-
amide (Omniscan) (Amersham Health Inc, Princeton, NJ)
were administered to mice through tail vein injection at a
dose of 0.04 mmol/kg of body weight. Magnetic resonance
imaging was performed before and 5 and 24 hours post-
contrast injection.
Images were obtained with a 4.7-T horizontal-bore INOVA
spectrometer (Varian) equipped with a 12-cm-diameter gra-
dient set having a maximum strength of 25 G/cm. Mice
were anesthetized with a 1% isoflurane air mixture deliv-
ered through a nose cone. The core body temperature was
monitored with a rectal probe connected to a small-animal
monitoring system (SA Inc., Stony Brook, NY) that main-
tained the core temperature at 37 ± 0.1jC by adjusting a
stream of heated air in the bore of the magnet. Mice were
placed prone on a fiberglass platform within a 50-mm-
diameter birdcage volume coil operating at 200.8 MHz.
Coronal and transverse T1-weighted images were acquired
through the abdomen (liver) and hind limb (tumor) of the
mouse with a spin-echo sequence (TR/TE = 500/15 milli-
seconds, matrix = 256  128, and FOV = 4  2 cm, slice
thickness = 1 mm, signal average = 4).
Imaging Data Analysis
Image contrast enhancement measurements were per-
formed to quantify the amount of contrast agent in specific
tissues. Contrast enhancement values were calculated by
relating the pixel intensity values, I, of the target tissue (liver
or tumor) to an unaffected tissue (skeletal muscle) according
to the following equation:
% Contrast enhancement ¼ ðRIpost  RIpreÞ=RIpre  100
where RIpost is the relative intensity (Iliver/Imuscle or Itumor/
Imuscle) after infusion, and RIpre is the relative intensity (Iliver/
Imuscle or Itumor/Imuscle) before infusion.
Statistical Evaluation
The results were expressed as mean ± standard error.
Analysis of variance (ANOVA) with Tukey’s multiple compar-
ison post hoc testing was used for evaluation of differences
between groups. Differences with a P value less than .05
were deemed significant.
Results
Preparation of Gd-DTPA-SA-LDL
Following the procedure of Jasanada et al., DTPA-SAwas
prepared with a 48% yield (0.45g). The purity of the product
was confirmed by TLC and matrix-assisted laser desorption
ionization-time of flight mass spectrometry. A dominant
molecular ion peak at 894.5 (m/z) verified the product
(DTPA-bis(stearylamide), MW = 896.4 g/mol). A stock solu-
tion of 3.0 mM DTPA-SA was added to a solution of LDL
yielding a final DTPA-SA/LDL molar ratio of 200:1. Based on
zinc dithizone assay, 70% to 90% intercalation efficiency
was achieved, resulting in approximately 150 to 180 DTPA-
SA molecules per LDL particle. Labeling ratios as high as
496:1 were subsequently achieved, but the in vivo studies
were performed with chelate to protein ratios of f170:1.
The structure of Gd-DTPA-SA-LDL is shown schematically
in Figure 1.
Figure 1. Structure of Gd-DTPA-SA-LDL.
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Size Measurements
Light scattering Figure 2 depicts the particle size distribu-
tion of native LDL and Gd-DTPA-SA-LDL analogs at probe to
protein ratios of 154:1, 334:1, and 496:1. One can see that
the size distribution curves of the Gd-DTPA-SA-LDL analogs
are closely superimposed on that of native LDL. Mean
particle diameters were 27.7, 26.3, 27.2, and 30.7 nm for
native LDL, Gd-DTPA-SA-LDL 154:1, 334:1, and 496:1, re-
spectively. The size distribution of LDL particles with up to
334 Gd-DTPA-SA chelates was similar to that of native LDL
but at higher payloads (496) there was a slight right sift of
the particle size distribution.
Transmission electron microscopy Negative staining elec-
tron microscopy of native LDL and Gd-DTPA-SA-LDL
revealed uniform spherical particles of comparable size
(Figure 3). In Table 1, measurements of particle size diam-
eter revealed that Gd-labeled LDL at payloads of 230:1 and
496:1 (25.0 ± 4.0 and 25.7 ± 2.8 nm, respectively) were
larger than native LDL (21.2 ± 2.5 nm) (P < .0001).
Agarose Gel Electrophoresis
Agarose gel electrophoresis was performed on Gd-
DTPA-SA-LDL particles with payloads of 245:1 and 450:1
(Figure 4). Native and acetylated LDL served as controls.
Gd-DTPA-SA-LDL (245:1) displayed an identical migratory
pattern as native LDL, whereas Gd-DTPA-SA-LDL (450:1)
migrated slightly further than native LDL. As expected,
acetylated LDL showed a marked increase in its electropho-
retic mobility. These findings indicate that intercalating up to
245 Gd-DTPA-SA moieties into the LDL phospholipid mono-
layer does not alter the valence or surface charge density of
LDL. At higher payloads (450 Gd-DTPA-SA) the LDL par-
ticles exhibit a slight increase in electrophoretic mobility.
Relaxivity Measurements
The r1 relaxivity for Omniscan and Gd-DTPA-SA-LDL at
various temperatures are listed in Table 2. The relaxivity of
Omniscan was slightly higher at 21jC (4.2 mM1 s1) com-
pared to that at 40jC (3.5 mM1 s1). These values are
consistent with previous temperature-dependent r1 mea-
surements of Omniscan. The relaxivity per Gd(III) ion of
Gd-DTPA-SA-LDL did not show a temperature-dependent
effect (7.9 ± 0.22 and 8.1 ± 0.19 mM1 s1 at 21 and 40jC,
respectively). Given these values and the fact that these
LDL particle have approximately 180 amphiphilic Gd che-
lates, the r1 relaxivity per LDL molecule is estimated to
be 1440 mM1 s1.
Assessment of LDLR-Mediated Uptake
of Gd-DTPA-SA-LDL
In vitro MRI experiments Figure 5 shows representative
T1-weighted sagittal images of HepG2 and ldlA7 cells after
5 hours’ incubation with Gd-DTPA-SA-LDL (0.44 mM). In
these images, the cell pellets can be distinguished from the
overlaying PBS. The cell pellet of HepG2 treated with Gd-
labeled LDL showed higher signal intensity (23% higher)
compared with untreated HepG2 cells. Conversely, the low
signal intensity detected in treated ldlA7 did not differ from
untreated ldlA7 controls. When the corresponding Gd-DTPA-
SA-LDL–treated groups were compared, marked signal
enhancement (34% higher) is seen in HepG2 over ldlA7.
Finally, for HepG2 cells treated with Gd-labeled LDL and a
Figure 2. Particle size distributions of native LDL and Gd-DTPA-SA-LDL
analogs with various Gd-DTPA-SA/LDL ratios.
Figure 3. Electron microscopy of native LDL (A) and Gd-DTPA-SA-LDL (230:1 and 496:1) (B and C, respectively).
Table 1. Diameter Measurements of Native and Gd-DTPA-SA-LDL.
Diameter (nm) N
Native LDL 21.2 ± 2.5 31
Gd-DTPA-SA-LDL (230:1) 25.0 ± 4.0* 30
Gd-DTPA-SA-LDL (496:1) 25.7 ± 2.8* 30
*P < .0001 versus native LDL.
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six-fold excess of native LDL, no signal enhancement was
seen in the cell pellet. This indicates that native LDL effec-
tively inhibited the uptake Gd-DTPA-SA-LDL in HepG2 cells.
Confocal microscopy experiments During the reconstitu-
tion process 338 molecules of SiPc-BOA were incorporated
into the core of LDL. Thereafter, 160 molecules of Gd-DTPA-
SA were intercalated into the phospholipids monolayer of the
SiPc-BOA-LDL particle.
Figure 6 shows the confocal fluorescent images of HepG2
cells incubated with the diagnostic probes under various
conditions. Figure 6, A and A´ displays images of cells alone
(no nanoparticle), which demonstrate the absence of signifi-
cant background fluorescence in the cells. When the cells
were incubated with 240 g/ml Gd-DTPA-SA(r-SiPc-BOA)-
LDL at 37jC for 4 hours, marked fluorescence was observed
within the cells’ cytosol (Figure 6, B and B´), indicating active
uptake and internalization. Similarly, in the presence of LDL
reconstituted with 240 g/ml of SiPc-BOA, intense intracellular
fluorescence was also observed (Figure 6, D and D´). Finally,
competition experiments were performed in which HepG2
cells were incubated with 240 g/ml Gd-DTPA-SA(r-SiPc-
BOA)-LDL and with a 25-fold excess of unlabeled native
LDL. All intracellular fluorescence was inhibited under these
conditions (Figure 6, C and C´).
In vivo MRI experiments Representative T1-weighted axial
images through the abdomen and hind limbs from a tumor-
bearing mouse after IV administration of Gd-DTPA-SA-LDL
(170:1) (0.04 mmol/kg) are displayed in Figure 7 and coronal
images are shown in Figure 8. In precontrast images, there
was little intrinsic signal contrast between the liver paren-
chyma/ dorsal thoracic muscle and tumor/leg muscle. At
5 hours postcontrast administration, marked signal enhance-
ment was apparent in the liver, whereas minimal contrast
enhancement was exhibited by the tumor. By 24 hours,
signal enhancement within the tumor increased dramatically
and clear demarcation of the boundary of the tumor was
evident. These levels of tissue contrast were sustained
through 36 hours.
Control experiments were also performed in which the
commercial Gd-DTPA-diamide chelate, Omniscan/gadodi-
amide, was administered to a tumor-bearing mouse. Figure 9
shows the MR images before and 5 and 24 hours after IV
injection of gadodiamide (0.04 mmol/kg body weight). Five
hours after administration of gadodiamide minimal signal
enhancement was detected in the liver, as most of the
contrast agent was expected to be cleared. At this time, no
enhancement was evident in the tumor. By 24 hours, the
signal in the liver returned to the precontrast levels and the
tumor remained unenhanced. At 5 hours, accumulation of
gadodiamide within the mouse’s urinary bladder was evi-
dent. Given that gadodiamide is rapidly cleared from the
body within 3 to 5 hours by renal elimination, these findings
are expected.
Table 3 presents the calculated mean contrast enhance-
ment values from the in vivo MRI experiments. At 5 hours,
significantly higher contrast enhancement was detected in
the liver after Gd-DTPA-SA-LDL administration compared
to Omniscan treatment (55.40 ± 6.20% and 6.28 ± 5.38%,
respectively). Higher enhancement values were also ob-
served in tumors with Gd-DTPA-SA-LDL versus Omniscan
(9.40 ± 3.12% vs 0.63 ± 0.63%, respectively). At 24 hours,
enhancement of the liver decreased to about half its 5-hour
value (25.60 ± 4.50%), but it was still significantly higher than
that of Omniscan controls (3.33 ± 3.33%). Concurrently,
tumor contrast enhancement rose markedly in animals given
Gd-DTPA-SA-LDL (25.60 ± 2.50%) and was significantly
greater than the enhancement of Omniscan-treated con-
trols (0.57 ± 0.57%).
Discussion
The capability of actively targeted contrast agents to serve
as biological markers and surrogate endpoints plays a cen-
tral role in molecular imaging. To date, a variety of conjugated
ligands, which include antibodies, peptides, and peptidomi-
Figure 4. Agarose gel electrophoresis of native and modified LDL species. 1.
Acetylated LDL; 2. Gd-DTPA-SA-LDL (245:1); 3. Gd-DTPA-SA-LDL (450:1);
4. Native LDL.
Table 2. T1 Relaxivities of Omniscan and Gd-DTPA-SA-LDL.
Parameter Contrast Agent
Omniscan Gd-DTPA-SA-LDL
Gd/molecule 1 180
Relaxivity/Gd, temperature
21jC 4.2 7.9 ± 0.22
40jC 3.5 8.1 ± 0.19
Relaxivity/molecule, temperature
21jC 4.2 1440*
40jC 3.5 1440*
Relaxivity measurements were performed at 60 MHz. T1 relaxivity of contrast
agents are expressed in millimoles per liter per second. Data for Gd-DTPA-
SA-LDL is expressed as mean ± standard error (n = 3 and 4 for mea-
surements at 21 and 40jC, respectively).
*Estimated T1 relaxivity of Gd-labeled LDL molecule with 180 amphiphilic
Gd chelates.
Figure 5. T1-weighted saggital spin-echo images of HepG2 and ldlA7 cells
after a 5-hour incubation with Gd-DTPA-SA-LDL. Cells not incubated with
Gd-DTPA-SA-LDL served as untreated controls. Treated cells were
incubated with 0.44 mM Gd-DTPA-SA-LDL. The inhibition study was
conducted with a six-fold excess of native LDL.
MRI of LDL Receptors Corbin et al. 493
Neoplasia . Vol. 8, No. 6, 2006
metics, have been used to home synthetic nanoparticles to
specific biological targets [11–13,15,16]. The LDL nanopar-
ticle has a ‘‘built-in’’ targeting component. ApoB-100 is a
surface transmembrane glycoprotein that directs LDL to
cells expressing LDLR. Through electrostatic interactions
between cationic amino acid clusters on ApoB-100 and
LDLR, a series of events are activated to initiate receptor-
mediated endocytosis and the delivery of the LDL cargo to
the cell. Whereas cholesterol and triglycerides are the natu-
ral payloads for the LDL system, in the present study we
have modified LDL by intercalating an amphiphilic Gd-
DTPA chelate into the LDL phospholipid monolayer thereby
providing a means for selective delivery of Gd(III) to LDLR-
expressing tissues.
After surface modification of LDL, retention of avidity for
LDLR is essential if selective delivery of paramagnetic con-
trast agents is to be observed. Unlike nuclearmedicine where
only a few molecules of contrast agent are needed for de-
tection [10], a much greater number of paramagnetic probes
must be conjugated onto the nanoplatform due to the lower
sensitivity of MRI. This is a particularly important issue, as
extensive surface modification of LDL can alter the affinity
of this lipoprotein for LDLR [43,44]. The first series of experi-
ments were performed to examine the structure and func-
tional properties of the Gd-labeled LDL nanoparticle. Those
methods that measured the physical dimensions of the
particles (light-scattering photon correlation spectroscopy
and transmission electron microscopy) provided slightly dif-
ferent findings. Light-scattering measurements revealed
that the mean particle size and distribution of Gd-labeled
LDL was similar to native LDL. Meanwhile, electron micros-
copy indicated that the diameter of Gd-labeled LDL was
larger than that of unlabeled LDL. Additional experiments
that examined the surface charge and hydrodynamic prop-
erties of the Gd-LDL nanoparticles (agarose gel electropho-
resis) showed that intercalation of amphiphilic Gd-DTPA
Figure 6. Confocal fluorescent images of HepG2 cells incubated with Gd-DTPA-SA(r-SiPc-BOA)-LDL probes (A,B,C,D) at 37jC for 4 hours as well as the
corresponding bright field images (A´, B´, C´, D´). A and A´, cell alone control; B and B´, cell + 240 g/ml Gd-DTPA-SA(r-SiPc-BOA)-LDL; C and C´, cell + 240 g/ml
probe + 25-fold excess of native LDL; D and D´, cell + 240 g/ml r-SiPc-BOA-LDL
Figure 7. T1-weighted axial spin-echo images through the abdomen and
lower flank of a nude mouse with a subcutaneously implanted HepG2 tumor.
Images are from the mouse before administration of Gd-DTPA-SA-LDL
(precontrast) and at various times after the IV administration of MR contrast
agent (5, 24, and 36 hours). Long arrow indicates tumor; short arrowhead
indicates liver parenchyma.
Figure 8. T1-weighted coronal spin-echo images of a nude mouse with a
subcutaneously implanted HepG2 tumor. The sequence of images is the
same as that listed in Figure 5.
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chelates (up to 245 molecules) into the LDL phospholipid
monolayer did not alter the valence or surface charge den-
sity of LDL. This is not surprising because the Gd-DTPA-SA
group is neutral and because Apo-B100 probably contains
most of the charged groups in the particle. Not only were
the physical properties of Gd-labeled LDL unaltered relative
to its native counterpart, but both MRI and confocal micros-
copy cell experiments demonstrated that Gd-DTPA-SA-
LDL retained its affinity for LDLR. The absence of particle
uptake by ldlA7 cells (LDLR-deficient cells) and its clear
inhibition by native LDL in HepG2 cells provide strong evi-
dence that Gd-labeled LDL selectively binds to and is taken
up through LDLR. Hence, binding of the Gd-chelating group
did not distort or interfere with the receptor-binding moieties
on the protein component of the particle, as it should not if
the chelates intercalated into the phospholipid monolayer
as they were designed to do.
The remaining issue was determination if the uptake of
Gd(III) was sufficient for selective enhancement/visualization
of LDLR-expressing tissues in vivo. Figures 6 and 7 show
that LDLR-containing tissues (liver and HepG2 tumors) dis-
played significant MRI contrast enhancement after the IV
administration of Gd-labeled LDL, albeit with different ki-
netics. Hepatic enhancement was seen early (5 hours) and
tumor contrast became evident 24 hours postinjection,
whereas liver enhancement diminished over the later time
interval to about half its initial value. The differences in the
‘‘time to enhancement’’ between the two tissues can be
explained by the differences in tissue mass and blood flow.
The liver, a vital organ in mammals that occupies much of
the upper abdomen, receives 25% of the cardiac output [45].
Thus, a large portion of the injected dose of Gd-labeled
LDL will be readily accessible to the LDLR on the surface
of hepatocytes. As such, high concentrations of Gd-labeled
LDL will be sequestered within the liver within a short period.
Conversely, the HepG2 tumor xenograft accounted for only
approximately 1% of the animal’s body weight and is sup-
plied by sporadic and tortuous blood vessels. Under these
conditions, a longer time would be required for sufficient con-
centrations of Gd-labeled LDL to reach and be taken up by
the tumor for in vivo detection. By 24 hours, significant ac-
cumulation of Gd-labeled LDL is seen in the tumor, whereas
in the liver, active clearance of the amphiphilic Gd complex
(through biliary elimination) is under way such that the
percent contrast enhancement between the two tissues are
approximately equal at this point.
Both the in vitro and in vivo findings of the present study
demonstrate that LDL is an appealing nanoplatform for MR
molecular imaging. A similar approach was undertaken by
Frias et al. [46], who performed a fine study utilizing para-
magnetic HDL-like particles to image atherosclerotic plaques
in apoE knockout mice. Close examination of the LDL system
reveal intriguing aspects of this particulate imaging platform.
First, amphiphilic paramagnetic chelates (DTPA) can be
incorporated into the phospholipid monolayer of LDL without
interfering with targeting of the nanoparticle. The orientation
of these chelates on LDL exposes the Gd(III) ions to the sur-
rounding aqueous environment where they can interact
with local water molecules. In the present study, up to 180
of these chelates were intercalated into one LDL particle.
Typically, incorporation of Gd(III) chelates onto such macro-
molecules drastically increases the relaxivity of the individ-
ual Gd(III) ions [47–49]. This occurs as the Gd(III) chelate
adopts the slower rotational correlation time of the macro-
molecule [50]. Interestingly, the relaxivity of the amphiphilic
Gd(III) chelate on LDL only showed a marginal increase over
the small-molecule Gd(III) chelate, Omniscan. In addition,
temperature-dependent changes in the relaxivity of the am-
phiphilic Gd(III) chelates on LDL were also not observed.
This result would suggest that conflicting factors are involved
that limit the relaxivity of these particles. These factors may
include 1) high internal flexibility of the amphiphilic Gd(III)
chelate on LDL and/or 2) reduced access of water to the
Gd(III) center. Given that the two long sterylamide fatty acyl
chains anchor the Gd-DTPA into the LDL phospholipid mono-
layer, it is unlikely that the Gd(III) chelate will experience a
high degree of rotational freedom. However, water exchange
at the Gd(III) centers near the phospholipids surface of LDL
may be diminished. Unlike other liposomal/microemulsion/
micelle particulate MRI contrast agents, LDL contains the
large ApoB-100 at its surface. At a molecular weight of
Figure 9. T1-weighted axial spin-echo images through the abdomen and lower
flank of a nude mouse with a subcutaneously implanted HepG2 tumor. The
images are from the mouse before administration of gadodiamide (pre-
contrast) and at 5 and 24 hours after the IV administration ofMR contrast agent.
Long arrow indicates tumor; short arrowhead indicates liver parenchyma.
Table 3. Percent Contrast Enhancement after Administration of Omniscan or
Gd-DTPA-SA-LDL (0.04 mmol/kg).
Tissue 5 hours 24 hours
Omniscan
(n = 3)
Gd-LDL
(n = 5)
Omniscan
(n = 3)
Gd-LDL
(n = 5)
Liver 6.28 ± 5.38 55.40 ± 6.20* 3.33 ± 3.33 25.60 ± 4.50*
Tumor (HepG2) 0.63 ± 0.63 9.40 ± 3.12 0.57 ± 0.57 25.60 ± 2.50*
Percent enhancement is relative to precontrast levels in respective tissues.
Values are means ± standard error (n = 5). Gd-DTPA-SA-LDL payload 170:1.
*P < .05 versus respective control (Omniscan) group.
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550 kDa, ApoB-100 is one of the largest monomeric proteins
known [51]. Containing both hydrophilic and hydrophobic
domains, ApoB-100 spans the phospholipids monolayer
and occupies between 40% and 60% of the surface area of
LDL [51]. Due to the close proximity of the Gd(III) chelate to
the hydrophilic portions of ApoB-100 that extend into the
aqueous surface of LDL, electrostatic interactions between
these components may occur, limiting the access of water to
and from the Gd(III) center. Consequently, such interaction
can significantly reduce the rate of water exchange. Similar
‘‘quenching’’ effects have previously been reported for other
Gd(III) complexes bound to macromolecules [52–54]. Al-
though apoA-1 is much smaller than ApoB-100, such inter-
actions may also explain the moderate relaxivities reported
for HDL-like paramagnetic nanoparticles [46]. Despite this
shortcoming, the relaxivity of the entire Gd-DTPA-SA-LDL
molecule is still quite high (estimated 1440 mM1 s1). The
higher relaxivity of theGd-LDL complex should provide signal
enhancement at much lower local concentrations than tradi-
tional low molecular weight paramagnetic chelates.
Another interesting aspect of the LDLR system is its
receptor-mediated uptake mechanism. Receptor-mediated
endocytosis is a highly specific/high-capacity process that
can concentrate many molecules of LDL inside the cell within
a relatively short time [22]. Once internalized, LDLR disso-
ciates from LDL and is recycled back to the cell surface
where it is available to interact with many more Gd-LDL over
its lifetime [22]. With a recycle time of approximately 10 min-
utes and a lifetime of about 24 hours, one can assume that
each receptor mediates the transport of approximately
144 LDL particles into LDLR-expressing cells each day.
Assuming approximately 1000 receptors per cell, this pro-
vides an extremely efficient system for delivery of its natural
cargo of cholesterol (f1500 cholesterol esters plus addi-
tional free cholesterol) and fatty acids. This system offers an
attractive means for targeted delivery of contrast agents, as
this process of receptor recycling provides an ample mech-
anism for signal amplification. However, one must be aware
that downregulation of LDLR can alter the uptake kinetics of
Gd-DTPA-SA-LDL. The cell surface expression of LDLR is
regulated by cellular cholesterol concentrations [55], thus,
on first pass extraction of exogenous LDL intracellular con-
centrations of cholesterol may rise, causing a negative feed-
back ‘‘retraction’’ of LDLR. Consequently, the uptake kinetics
of these administered particles would be slower than that
described above. One way of overcoming this limitation
would be to replace/reduce the cholesterol-ester core with
another lipophilic biomolecule, thereby avoiding the choles-
terol induced LDLR down regulation.
The issue of nonspecific binding of LDL particles is also
realized. Indeed, the intercalation method provides a versa-
tile means of introducing contrast agents onto LDL; however,
in this location amphiphilic molecules have a tendency to
undergo nonspecific exchange with the outer phospholipids
membrane of cells. To avoid this, it is essential to anchor the
surface-bound chelate with a long, hydrophobic group that
may penetrate into the underlying lipid core of the particle.
Hook-shaped anchors consisting, for example, of cis-linoleic
acid as opposed to linear stearic acid are preferable. Non-
specific transfer to cell surface bilayers would dilute the
labeling of LDL and reduce the specificity of LDLR targeting.
Secondly, LDLR is not the only surface receptor with affinity
for native LDL. The receptors LBS (lipoprotein binding site),
SR-B1/CLA-1 (scavenger receptor class B type I/CD36- and
LIMPII-analogous-1), and CD36 have all been shown to bind
LDL and participate in the selective-uptake LDL-derived
cholesterol [56–59]. Because the majority of these observa-
tions were made in cell culture, it remains uncertain how
much these receptors contribute to the catabolism of LDL
in vivo. Nonspecific uptake of Gd-LDL by the reticulum
endothelium system in the liver may also interfere with tar-
geted delivery of this probe. Pegylation of the particle may
render it more ‘‘stealthy’’ and mitigate this problem. Clearly,
further studies are required to investigate these non-LDLR
uptake processes.
Despite these caveats the present study demonstrates
that the current formulation of Gd-labeled LDL is a simple,
natural, nonimmunogenic effectively targeted contrast agent
that enables one to image the LDLR in vivo. Several clinical
applications for Gd-labeled LDL can be proposed; Gd-LDL
may be used in the localization and detection of tumors that
overexpress LDLR. Nononcologic applications could include
detection for early atherosclerotic disease [60], monitoring
the efficacy of gene therapy for familial hypercholesterolemia
[61] as well as providing an alternative means for contrast-
enhanced imaging of the adrenal glands [62].
The opportunity for multimodality MR/optical imaging
approaches was also demonstrated in this study. By intro-
ducing MRI and optical probes as separate components of
the LDL platform, it offers the flexibility to adjust the concen-
trations of the individual agents such that variable payloads
of Gd(III) and optical probes can be incorporated into LDL.
This approach provides optimal diagnostic capabilities of
these imaging modalities—the high resolution, deep pene-
tration, and excellent soft tissue contrast of MRI and the high
sensitivity, economy, and portability of optical fluorescence
imaging. In addition, SiPc-BOA is a potent photosenitizer
[63] suitable for photodynamic therapy.
The potential of incorporating traditional therapeutics into
LDL has long been recognized and exploited [64,56,66].
Hydrophobic drugs such as doxorubicin, taxol, and vindesine
have been incorporated into LDL by simple incubation or
reconstitution methods [64–67]. This approach is not limited
only to hydrophobic drugs; lipophilic derivatives of drugs of
moderate hydrophilicity can also be prepared and incorpo-
rated into LDL [68,69]. Several studies demonstrated that
LDL can serve as an effective carrier of anticancer drugs that
is capable of significantly enhancing cytotoxicity in various
tumor cells [67,70–73]. Introducing both imaging agents and
therapeutics into LDL offers the possibility of having a truly
multifunctional nanoplatform capable of detection and treat-
ment by a single intervention.
Recently, our laboratory has shown that by conjugating
homing ligands onto the surface of ApoB-100, LDL can be
redirected to alternate cell surface receptors and epitopes
[74]. This was demonstrated by conjugating folic acid to the
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lysine residues of ApoB-100; subsequent confocal studies
demonstrated uptake by folate receptor–mediated path-
ways, whereas LDLR uptake was blocked. To date, a diverse
set of disease-homing molecules exist that could potentially
be used to functionalize LDL as a multifunctional targeting
platform [17–20,75–77]. The design of such a versatile
biocompatible nanoplatform would not only greatly expand
the possible application of LDL nanoparticles in diagnostic
imaging but also in the field of targeted therapeutics.
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